REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS (Tables)

12 Months Ended

Dec. 31, 2021

REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Year Ended December 31,
(In thousands)	2021			2020			2019
Royalties from a related party    - RELVAR/BREO	$	234,066		$	221,536		$	189,424
Royalties from a related party    - ANORO		44,935			45,992			42,625
Royalties from a related party    - TRELEGY		126,688			73,089			42,790
Total royalties from a related party		405,689			340,617			274,839
Less: amortization of capitalized    fees paid to a related party		(13,823	)		(13,823	)		(13,823	)
Royalty revenue		391,866			326,794			261,016
Strategic alliance - MABA program		—			10,000			—
Total net revenue from GSK	$	391,866		$	336,794		$	261,016